2I6B image
Deposition Date 2006-08-28
Release Date 2007-01-02
Last Version Date 2023-08-30
Entry Detail
PDB ID:
2I6B
Keywords:
Title:
Human Adenosine Kinase in Complex with An Acetylinic Inhibitor
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.30 Å
R-Value Free:
0.29
R-Value Work:
0.22
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Adenosine kinase
Chain IDs:A, B
Chain Length:345
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Crystal structures of human adenosine kinase inhibitor complexes reveal two distinct binding modes.
J.Med.Chem. 49 6726 6731 (2006)
PMID: 17154503 DOI: 10.1021/jm060189a

Abstact

Adenosine kinase (AK) is an enzyme responsible for converting endogenous adenosine (ADO) to adenosine monophosphate (AMP) in an adenosine triphosphate- (ATP-) dependent manner. The structure of AK consists of two domains, the first a large alpha/beta Rossmann-like nucleotide binding domain that forms the ATP binding site, and a smaller mixed alpha/beta domain, which, in combination with the larger domain, forms the ADO binding site and the site of phosphoryl transfer. AK inhibitors have been under investigation as antinociceptive, antiinflammatory, and anticonvulsant as well as antiinfective agents. In this work, we report the structures of AK in complex with two classes of inhibitors: the first, ADO-like, and the second, a novel alkynylpyrimidine series. The two classes of structures, which contain structurally similar substituents, reveal distinct binding modes in which the AK structure accommodates the inhibitor classes by a 30 degrees rotation of the small domain relative to the large domain. This change in binding mode stabilizes an open and a closed intermediate structural state and provide structural insight into the transition required for catalysis. This results in a significant rearrangement of both the protein active site and the orientation of the alkynylpyrimidine ligand when compared to the observed orientation of nucleosidic inhibitors or substrates.

Legend

Protein

Chemical

Disease

Primary Citation of related structures